Shots: The termination is based on results from P-IIb study, assessing Novexatin vs PBO, which was unable to meet a main goal of study under FDA guidelines with no superiority over PBO In 2013, Taro entered into license and co-development agreement with NovaBiotics for its novel antifungal peptide Novexatin Novexatin is a fast-acting topical drug […]Read More
